Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine

Clin Infect Dis. 2004 Sep 1;39(5):641-8. doi: 10.1086/422653. Epub 2004 Aug 16.

Abstract

Background: Invasive pneumococcal disease (IPD) is a burgeoning problem, with rates of antibiotic-nonsusceptible IPD, in particular, increasing during the past decade. One measure to combat IPD is vaccination with the recently introduced 7-valent pneumococcal conjugate vaccine (PCV).

Methods: To evaluate the effects of the introduction of PCV in 2000 on the epidemiology of antibiotic-nonsusceptible IPD, a database of IPD cases from January 1995 through December 2002 identified through active surveillance in 5 Tennessee counties was examined. For each case, clinical data were collected, and antibiotic susceptibility testing and serotyping were performed on available isolates.

Results: Among children younger than 2 years, IPD rates peaked at 235 cases per 100,000 in 1999 before decreasing, after PCV licensure, to 46 cases per 100,000 in 2002 (P<.001). The proportion of penicillin-nonsusceptible IPD isolates from this age group declined from 59.8% in 1999 to 30.4% in 2002 (P<.01). After 2001, similar decreases in IPD rates and in the proportion of antibiotic-nonsusceptible isolates recovered were seen among persons aged 2 years and older (P<.01). Rates of IPD due to PCV-associated serotypes declined after PCV introduction in all age groups (P<.001), whereas the rate of IPD due to nonvaccine serotypes increased among persons aged 2 years and older.

Conclusions: In the 2 years since licensure, widespread PCV vaccination of children has resulted in dramatic declines in the proportion of antibiotic-nonsusceptible isolates in Tennessee. PCV vaccination of children also appears to be a highly effective method for reducing the burden of IPD in adults.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / physiology
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Microbial Sensitivity Tests / methods
  • Middle Aged
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / therapeutic use*
  • Population Surveillance / methods
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / immunology*
  • Streptococcus pneumoniae / metabolism
  • Streptococcus pneumoniae / physiology
  • Tennessee / epidemiology
  • Vaccines, Conjugate / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Pneumococcal Vaccines
  • Vaccines, Conjugate